$2.31T
Total marketcap
$74.25B
Total volume
BTC 56.38%     ETH 9.81%
Dominance
us

Zai Lab ZLAB Stock

$19.47   -0.764534%
Add to favorites
Market Cap
$2.20B
LOW - HIGH [24H]
$19.27 - $20.49
VOLUME [24H]
$162.67K
P/E Ratio
0
Earnings per share
-$1.63
ISIN
US98887Q1040
Price   Prediction

Zai Lab Price Chart

Sorry, that's all we've gotfor now...

Zai Lab ZLAB Financial and Trading Overview

Zai Lab stock price 19.47 USD
Previous Close 20.49 USD
Open 20.45 USD
Bid 14.46 USD x 200
Ask 25.35 USD x 200
Day's Range 19.56 - 20.48 USD
52 Week Range 15.96 - 41.2 USD
Volume 1.38M USD
Avg. Volume 909.48K USD
Market Cap 2.22B USD
Beta (5Y Monthly) 0.762
PE Ratio (TTM) N/A
EPS (TTM) -1.63 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 33.3 USD

ZLAB Valuation Measures

Enterprise Value 1.77B USD
Trailing P/E N/A
Forward P/E -11.237822
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4.887797
Price/Book (mrq) 3.2902904
Enterprise Value/Revenue 3.916
Enterprise Value/EBITDA -7.819

Trading Information

Zai Lab Stock Price History

Beta (5Y Monthly) 0.762
52-Week Change -40.22%
S&P500 52-Week Change 20.84%
52 Week High 41.2 USD
52 Week Low 15.96 USD
50-Day Moving Average 18.83 USD
200-Day Moving Average 20.93 USD

ZLAB Share Statistics

Avg. Volume (3 month) 909.48K USD
Avg. Daily Volume (10-Days) 924.4K USD
Shares Outstanding 112.92M
Float 91.71M
Short Ratio 7.59
% Held by Insiders 2.15%
% Held by Institutions 31.25%
Shares Short 8.15M
Short % of Float 7.36%
Short % of Shares Outstanding 7.21%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) March 31, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -39.29%
Operating Margin (ttm) -69.65%
Gross Margin 8.10%
EBITDA Margin -50.082%

Management Effectiveness

Return on Assets (ttm) -13.35%
Return on Equity (ttm) -24.18%

Income Statement

Revenue (ttm) 453.28M USD
Revenue Per Share (ttm) 4.11 USD
Quarterly Revenue Growth (yoy) -6.50%
Gross Profit (ttm) 36.75M USD
EBITDA -227012000 USD
Net Income Avi to Common (ttm) -178115008 USD
Diluted EPS (ttm) -1.7
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 661.32M USD
Total Cash Per Share (mrq) 5.89 USD
Total Debt (mrq) 231.91M USD
Total Debt/Equity (mrq) 35.03 USD
Current Ratio (mrq) 2.404
Book Value Per Share (mrq) 5.963

Cash Flow Statement

Operating Cash Flow (ttm) -101002000 USD
Levered Free Cash Flow (ttm) -73355376 USD

Profile of Zai Lab

Country United States
State N/A
City Pudong
Address Building B
ZIP 201203
Phone 86 21 6163 2588
Website https://www.zailaboratory.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1784

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Q&A For Zai Lab Stock

What is a current ZLAB stock price?

Zai Lab ZLAB stock price today per share is 19.47 USD.

How to purchase Zai Lab stock?

You can buy ZLAB shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Zai Lab?

The stock symbol or ticker of Zai Lab is ZLAB.

Which industry does the Zai Lab company belong to?

The Zai Lab industry is Biotechnology.

How many shares does Zai Lab have in circulation?

The max supply of Zai Lab shares is 112.92M.

What is Zai Lab Price to Earnings Ratio (PE Ratio)?

Zai Lab PE Ratio is now.

What was Zai Lab earnings per share over the trailing 12 months (TTM)?

Zai Lab EPS is -1.63 USD over the trailing 12 months.

Which sector does the Zai Lab company belong to?

The Zai Lab sector is Healthcare.

Zai Lab ZLAB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.symbol }} {{ item.name }} {{ item.symbol }} {{ item.country.toUpperCase() }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
us US Tech Composite IXIC US 26116.85 USD
+0.94
3.25B USD 25912.4 USD 26164.55 USD 3.25B USD
us Stlmt ID US Tech Biotechnology NBX US 3995.9 USD
-4.37
4555.41 USD 4917.8 USD
us US Tech Golden Dragon China HXC US 6116.02 USD
+0.06
6110.7 USD 6163.9 USD
us US Tech Global Market Composite NQGM US 2306.27 USD
+1.33
2282.75 USD 2306.4 USD
us US Tech Biotechnology NBI US 6536.02 USD
-0.16
6486.53 USD 6537.98 USD
us US Tech Health Care IXHC US 1245.42 USD
-0.76
1237.77 USD 1248.69 USD
Select currency